American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 119-127 , July 2009

Effectiveness of Treatments for Metastatic Uveal Melanoma

,Accepted 27 January 2009.

References 

  1. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639–1643
  2. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665–1670
  3. Nathan FE, Berd D, Sato T, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16:201–208
  4. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89:1561–1158
  5. Egerer G, Lehnert T, Max R, et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol. 2001;6:25–28
  6. Char DH. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–389discussion 390
  7. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol. 1992;36:429–438
  8. Robertson DM. Cytogenetics in the management of uveal melanoma: are we there yet?. Arch Ophthalmol. 2008;126:409–410
  9. Brighton B, Bhandari M, Tornetta P, Felson DT. Hierarchy of evidence: from case reports to randomized controlled trials. Clin Orthop Relat Res. 2003;19–24
  10. Augsburger JJ, Corrêa ZM, Shaikh AH. Quality of evidence about treatment for metastatic uveal melanoma. Trans Am Ophthalmol Soc. 2008;106:128–135
  11. Pyrhönen S. The treatment of metastatic uveal melanoma. Eur J Cancer. 1998;34:S27–S30
  12. Wöll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 1999;9:575–581
  13. Jäckel A, Bock M, Deichmann M, et al. [Therapy of metastatic malignant uveal melanoma]. Hautarzt. 2001;52:98–103
  14. Bechrakis NE, Scheibenbogen C, Schmittel A, et al. [Choroid melanoma. Adjuvant therapy in high-risk patients and new therapy approaches in the metastatic stage]. Ophthalmologe. 2002;99:333–337
  15. De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment (A literature review). Bull Soc Belge Ophtalmol. 2002;286:59–63
  16. Feldman ED, Pingpank JF, Alexander HR. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 2004;11:290–297
  17. Rousseau AP. Uveal melanoma: update and future directions. Can J Ophthalmol. 2004;39:335–342
  18. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143–150
  19. Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006;46:133–149
  20. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151–166
  21. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008;34:247–258
  22. Cunningham JD, Cirincione E, Ryan A, et al. Indications for surgical resection of metastatic ocular melanoma (A case report and review of the literature). Int J Pancreatol. 1998;24:49–53
  23. Terheyden P, Kampgen E, Runger TM, et al. [Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature]. Hautarzt. 1998;49:770–773
  24. Fournier GA, Albert DM, Arrigg CA, et al. Resection of solitary metastasis (Approach to palliative treatment of hepatic involvement with choroidal melanoma). Arch Ophthalmol. 1984;102:80–82
  25. Gronemeyer U, Engemann R, Thiede A. [Successful removal of a liver metastasis 15 years after enucleation of a choroid melanoma]. Fortschr Ophthalmol. 1984;81:363–364
  26. Shields JA, Augsburger JJ, Donoso LA, et al. Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years. Am J Ophthalmol. 1985;100:666–668
  27. Tishler M, Greif J, Topilsky M. Solitary pulmonary metastasis of choroidal malignant melanoma simulating primary lung cancer. Eur J Respir Dis. 1986;68:215–217
  28. Carrasco CH, Wallace S, Charnsangavej C, et al. Treatment of hepatic metastases in ocular melanoma (Embolization of the hepatic artery with polyvinyl sponge and cisplatin). JAMA. 1986;255:3152–3154
  29. Shields JA, Shields CL, Augsburger JJ, Negrey JN. Solitary metastasis of choroidal melanoma to the contralateral eyelid. Ophthal Plast Reconstr Surg. 1987;3:9–12
  30. Coupland SE, Sidiki S, Clark BJ, et al. Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Arch Ophthalmol. 1996;114:751–756
  31. Gündüz K, Shields JA, Shields CL, et al. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol. 1998;125:407–409
  32. Massy J, Aouididi S, Si Ahmed K, et al. [Apropos of a rare case of bilateral orbital metastasis of malignant melanoma of the choroid]. J Fr Ophtalmol. 1998;21:529–534
  33. Midena E, de Belvis V, Dei Tos AP, Antonini C. Isolated brain metastasis of malignant choroidal melanoma 27 years after enucleation. Arch Ophthalmol. 1999;117:1553–1556
  34. Demirci H, Shields CL, Shields JA, et al. Bilateral breast metastases from choroidal melanoma. Am J Ophthalmol. 2001;131:521–523
  35. Camp R, Lind DS, Hemming AW. Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma. J Hepatobiliary Pancreat Surg. 2002;9:519–521
  36. Soni S, Lee DS, DiVito J, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol. 2002;24:488–491
  37. Shields JA, Perez N, Shields CL, et al. Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection. Ophthalmic Surg Lasers. 2002;33:416–420
  38. Grosjean J, Penel N, Gauthier H, Vanseymortier L. [Ultra-late metastasis of ocular melanoma: about two cases]. Rev Med Interne. 2004;25:147–149
  39. Duh EJ, Schachat AP, Albert DM, Patel SM. Long-term survival in a patient with uveal melanoma and liver metastasis. Arch Ophthalmol. 2004;122:285–287
  40. Saraiva VS, Rodriguez-Reyes AA, Chen MF, et al. Metastatic choroidal melanoma presenting as a solitary pulmonary nodule. Can J Ophthalmol. 2005;40:72–74
  41. Achtaropoulos AK, Mitsos AP, Detorakis ET, et al. Late isolated brain metastasis following enucleation for choroidal melanoma. Ophthalmic Surg Lasers Imaging. 2005;36:151–154
  42. Ueda H, Hamagami H, Tanaka H, et al. Combination hepatic arterial infusion therapy is effective for ocular melanoma metastasis to the liver. Oncol Rep. 2005;14:1543–1546
  43. Berger TG, Dieckmann D, Efferth T, et al. Artesunate in the treatment of metastatic uveal melanoma—first experiences. Oncol Rep. 2005;14:1599–1603
  44. Bourla DH, Young TA. Treatment considerations for primary uveal melanoma with choroidal metastasis to the fellow eye. Semin Ophthalmol. 2007;22:175–177
  45. Connolly G, Wladis E, Masselam K, Weinberg DA. Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma. Orbit. 2007;26:291–294
  46. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–2223
  47. Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712–720
  48. Siegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol. 2007;33:627–632
  49. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74:574–577
  50. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–336
  51. Flaherty LE, Unger JM, Liu PY, et al. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998;21:568–572
  52. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97:465–475
  53. Baldo S, Kodjikian L, Belli F, et al. [Liver metastases of choroid melanoma. Retrospective study of 63 cases]. Tumori. 2003;89:229–230
  54. Rivoire M, Kodjikian L, Baldo S, et al. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422–428
  55. Kodjikian L, Grange JD, Baldo S, et al. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2005;243:985–993
  56. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–389discussion 390
  57. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100:122–129
  58. Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076–8080
  59. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133:177–184
  60. Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007;17:225–231
  61. Keilholz U, Schuster R, Schmittel A, et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. Eur J Cancer. 2004;40:2047–2052
  62. Corrie PG, Shaw J, Spanswick VJ, et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer. 2005;92:1997–2003
  63. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–976
  64. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589–2595
  65. Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998;24:127–130
  66. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–3070
  67. Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:1115–1120
  68. Alexander HR, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343–6349
  69. Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67–72
  70. Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004;14:217–222
  71. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992;10:1919–1926
  72. Cantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver (Report of a phase II study). Tumori. 1994;80:37–39
  73. Proebstle TM, Scheibenbogen C, Sterry W, Keilholz U. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in ‘poor-risk' metastatic melanoma. Eur J Cancer. 1996;32A:1530–1533
  74. Ellerhorst JA, Bedikian AY, Smith TM, et al. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs. 2002;13:169–172
  75. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840–845
  76. Pyrhönen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366–2372
  77. Pföhler C, Cree IA, Ugurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs. 2003;14:337–340
  78. Schmidt-Hieber M, Schmittel A, Thiel E, Keilholz U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res. 2004;14:439–442
  79. Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297–304
  80. Schmittel A, Scheulen ME, Bechrakis NE, et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005;15:205–207
  81. Schmittel A, Schuster R, Bechrakis NE, et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005;15:447–451
  82. Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17:578–583
  83. O'Neill PA, Butt M, Eswar CV, et al. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res. 2006;16:245–248
  84. Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17:1826–1829
  85. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol. 1999;237:558–567
  86. Feinstein A. Clinical Epidemiology: The Architecture of Clinical Research. In: Philadelphia, Pennsylvania: Saunders; 1985;p. 323–324460–462
  87. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–1129

PII: S0002-9394(09)00096-8

doi: 10.1016/j.ajo.2009.01.023

American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 119-127 , July 2009

Article Tools